-53%

est. 2Y upside i

HealthcareSeries C

Rank

#2300

Sector

Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: Medium

Loyalfordogs presents a moderate upside opportunity (approximately 40% over a 2-year horizon) driven by its pioneering position in canine longevity drugs and recent positive FDA progress for LOY-002 and LOY-001.

Last updated: March 10, 2026

Bull (22%)+150%

Successful and timely FDA Expanded Conditional Approval and subsequent full approval for LOY-002 and LOY-001 by late 2026, leading to rapid market adoption and significant penetration of the $3.0B SAM, driving revenue to $150M+ by 2028 and justifying a valuation of over $1.0B.

Base (48%)+50%

LOY-002 and LOY-001 launch as anticipated with conditional FDA approval, achieving steady market penetration and moderate revenue growth, reaching $50M-$75M in revenue by 2028 and a valuation of $600M-$700M, representing a reasonable return on current valuation.

Bear (30%)-55%

Significant regulatory delays, unexpected clinical trial setbacks, or slower-than-anticipated market adoption for LOY-002 or LOY-001, leading to a down round or flat valuation around $200M-$250M, severely impacting common stock value due to the $250M liquidation preference.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

59%

Investors hold $250M in liquidation preferences ahead of common stock, representing 58.8% of the current $425M valuation.

Dilution Risk

high

Given the clinical stage, very high capital intensity, and unprofitability, significant future dilution from additional funding rounds is highly probable before an exit.

Secondary Liquidity

limited

A secondary market valuation of $409M exists, suggesting some limited opportunities for liquidity, but it is not an active or guaranteed mechanism.

Questions to Ask at the Interview

Strategic questions based on Loyalfordogs's data — designed to show you've done your homework.

  • 1

    “How is Loyal planning to maintain its strong competitive moat and defend against potential entry from larger animal health companies like Zoetis or Elanco, especially as the market for canine longevity drugs matures and proves profitable?”

  • 2

    “With product launches anticipated in early 2025 and late 2026, what are the specific revenue targets and market penetration goals Loyal is aiming for in the next 24-36 months to justify its current valuation and future funding needs?”

  • 3

    “Given the significant capital raised ($250M) relative to the current valuation ($425M) and the clinical stage of development, how does Loyal envision the path to liquidity for common shareholders, and what are the company's strategies for managing potential future dilution?”

Community

Valuation Sentiment

Our model estimates -53% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.